BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37093763)

  • 21. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
    Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
    Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
    Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
    Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.
    Ballester LY; Loghavi S; Kanagal-Shamanna R; Barkoh BA; Lin P; Medeiros LJ; Luthra R; Patel KP
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):395-403.e1. PubMed ID: 27268124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.
    Baer C; Dicker F; Kern W; Haferlach T; Haferlach C
    Leukemia; 2017 Jun; 31(6):1355-1362. PubMed ID: 27840426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].
    Timár B
    Magy Onkol; 2017 Mar; 61(1):6-11. PubMed ID: 28273183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Successful diagnosis of lymphoplasmacytic lymphoma with IgG paraprotein using MYD88 L265P mutation analysis].
    Abe M; Saburi M; Itani K; Kohno K; Soga Y; Kondo Y; Kawano Y; Nakayama T
    Rinsho Ketsueki; 2018; 59(6):695-697. PubMed ID: 29973445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma.
    Baloda V; Wheeler SE; Murray DL; Kohlhagen MC; Vos JA; Yatsenko SA; Agha ME; Djokic M; Swerdlow SH; Bailey NG
    Diagn Pathol; 2022 Aug; 17(1):63. PubMed ID: 35932039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis.
    Rossi D
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):113-8. PubMed ID: 25696843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
    Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
    Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].
    Ren Y; Zhou BQ; Xu Y; Fu CC; Shen HJ; Ding ZX; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Dec; 37(12):1054-1059. PubMed ID: 28088969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells.
    Ouk C; Roland L; Gachard N; Poulain S; Oblet C; Rizzo D; Saintamand A; Lemasson Q; Carrion C; Thomas M; Balabanian K; Espéli M; Parrens M; Soubeyran I; Boulin M; Faumont N; Feuillard J; Vincent-Fabert C
    Front Immunol; 2021; 12():641692. PubMed ID: 34017329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.
    Brunner A; Thalhammer-Thurner GC; Willenbacher W; Haun M; Zelger BG; Willenbacher E
    Ann Hematol; 2024 Feb; 103(2):553-563. PubMed ID: 37951851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly sensitive
    Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
    Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.
    Insuasti-Beltran G; Gale JM; Wilson CS; Foucar K; Czuchlewski DR
    Arch Pathol Lab Med; 2015 Aug; 139(8):1035-41. PubMed ID: 26230596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
    Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
    Mori N; Ohwashi M; Yoshinaga K; Mitsuhashi K; Tanaka N; Teramura M; Okada M; Shiseki M; Tanaka J; Motoji T
    PLoS One; 2013; 8(11):e80088. PubMed ID: 24224040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.
    Shekhar R; Naseem S; Binota J; Varma N; Malhotra P
    Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):231-239. PubMed ID: 33217360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.
    Kim JA; Im K; Park SN; Kwon J; Choi Q; Hwang SM; Sekiguchi N; Yoon SS; Lee DS; Kim SY
    Biomed Res Int; 2014; 2014():363540. PubMed ID: 24895570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities.
    Braggio E; Dogan A; Keats JJ; Chng WJ; Huang G; Matthews JM; Maurer MJ; Law ME; Bosler DS; Barrett M; Lossos IS; Witzig TE; Fonseca R
    Mod Pathol; 2012 May; 25(5):651-60. PubMed ID: 22301699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.